Bollengier F, Geerts A, Matton A, Mahler A, Velkeniers B, Hooghe-Peters E, Vanhaeist L
Laboratorium voor Farmacologie, Faculteit Geneeskunde en Farmacie, Vrije Universiteit Brussel, Belgium.
J Neuroendocrinol. 1993 Dec;5(6):669-76. doi: 10.1111/j.1365-2826.1993.tb00538.x.
Rat pituitary homogenates were submitted to differential and density gradient centrifugation. Subcellular fractions as well as the purified secretory granules were examined in electron microscopy, radioimmunological techniques, protease digestion, alkaline treatment and immunoblotting. The global outcome of these experiments was that: 1) the glycosylated rPRL was foremost recorded in the crude secretory granular fraction, also in the microsomal fraction and the cytosol, but virtually not in the plasma membrane fraction; 2) in purified secretory granules glycosylated rPRL appeared as an array of near Mr, such as was formerly obtained by enzymatic deglycosylation; 3) protease digestion and ice-cold alkaline treatment of the secretory granules showed that 23,000 rPRL appears in three different physicochemical states in these organelles: unsequestered within a closed system, membrane-bounded and bound state; 4) likewise treatment of microsomal vesicles showed that 23,000 and glycosylated rPRL are sequestered in these bodies, but apparently 23,000 rPRL appears as both integral membrane-bound and released from the lumen, whereas glycosylated rPRL is chiefly retained as an integral membrane protein. 5) dopamine alters the pattern of glycosylation as well in Mr as in relative percentages of the molecular variants. The systematical occurrence of the array of near Mr glycosylated rPRL is biosynthesized as a pool of proteins with a different degree of glycosylation. On the basis of our data, we speculate that selection of definite molecular variants from this pool could play an important role in the biological function of 23,000 rPRL and that oligosaccharides could perhaps target the glycosylated forms of rPRL to specific sites of action.
将大鼠垂体匀浆进行差速离心和密度梯度离心。采用电子显微镜、放射免疫技术、蛋白酶消化、碱性处理和免疫印迹等方法对亚细胞组分以及纯化的分泌颗粒进行检测。这些实验的总体结果如下:1)糖基化的重组催乳素(rPRL)主要存在于粗分泌颗粒组分中,也存在于微粒体组分和胞质溶胶中,但在质膜组分中几乎不存在;2)在纯化的分泌颗粒中,糖基化的rPRL呈现出一系列近似的相对分子质量(Mr),这与之前通过酶促去糖基化得到的结果一致;3)对分泌颗粒进行蛋白酶消化和冰冷碱性处理表明,23,000的rPRL在这些细胞器中呈现出三种不同的物理化学状态:在封闭系统中未被隔离、与膜结合以及处于结合状态;4)同样地,对微粒体囊泡的处理表明,23,000和糖基化的rPRL被隔离在这些小体中,但显然23,000的rPRL既以整合膜结合形式存在,也从内腔中释放出来,而糖基化的rPRL主要作为整合膜蛋白保留;5)多巴胺会改变糖基化模式,包括Mr以及分子变体的相对百分比。近似Mr的糖基化rPRL系列的系统出现是作为一组具有不同糖基化程度的蛋白质生物合成的。基于我们的数据,我们推测从这个池中选择特定的分子变体可能在23,000的rPRL的生物学功能中发挥重要作用,并且寡糖可能将rPRL的糖基化形式靶向特定的作用位点。